MALAT1 (Metastasis associated lung adenocarcinoma transcript 1)

Up-regulated MALAT1 subsequently sponged miR-690, leading to its functional depletion, autophagosome-lysosome fusion blockade, and aggravated lipid retention. Collectively, the METTL3-m6A/MALAT1/miR-690 axis orchestrates autophagy and lipid homeostasis, operationalizing an "m6A-long non-coding RNA (lncRNA)-microRNA (miRNA)" regulatory paradigm in NAFLD and offering an epitranscriptomic perspective on disease pathogenesis.

The amplification of PTK6 may serve as an early biomarker detectable at the HGA stage, while DEK amplification appears crucial for metastatic progression and may represent a therapeutic target. Further validation is needed.

Future research should prioritize paired tumor-node lncRNA profiling, validation of FNAB-based molecular assays, and integration of multi-omics data for predictive modeling. Overall, integrating lncRNA analysis into ultrasound-guided fine-needle aspiration biopsy may enhance the detection of occult nodal metastases in head and neck squamous cell carcinoma and support more accurate nodal staging in clinically node-negative patients.

Moreover, it enables not only single-cell quantification and accurate discrimination of MALAT1 and HOTAIR in cancerous and normal breast tissues, but also rapid imaging of dual lncRNAs in living cells. This proof-of-concept work shows promising potential in clinical diagnostics and postoperative monitoring.

The findings suggest that MALAT1 gene polymorphisms, particularly rs3200401 and rs619586, as well as the TCG haplotype, may influence susceptibility to non-Hodgkin lymphoma and serve as potential genetic biomarkers. However, further studies involving larger and ethnically diverse cohorts are required to validate these associations.

Bioinformatic analyses identified correlations between these lncRNAs and crucial genes involved in cell survival, migration, and angiogenesis, emphasizing possible lncRNA-miRNA-mRNA regulatory axes. The cardamom nanoemulsion demonstrates enhanced anticancer activity relative to the crude extract and could represent a novel therapeutic approach for colorectal cancer by modulating lncRNAs and related molecular pathways.

Finally, functional studies of MALAT1 in MCL primary samples showed that its levels were downregulated by microenvironmental stimuli and EZH2 activity, a known epigenetic factor induced by pro-proliferative stimuli and previously related with poor MCL prognosis. Altogether, these data support the favorable prognostic value of MALAT1 expression in MCL, and the MALAT1 dual role as oncogene or tumor suppressor in different neoplasms.

Our findings suggest that miR-20a-5p plays an oncogenic role in luminal breast cancer by promoting EMT, while MALAT1 may contribute to disease progression through indirect regulatory mechanisms. Finally, MALAT1 and miR-20a-5p might serve as potential therapeutic and prognostic targets in LBC.

This study presents a method to improve the therapeutic effect of methotrexate against rheumatoid arthritis using the Exo/MTX/HA.

The quantitative evidence from numerous in vitro and in vivo studies has consistently demonstrated that flavonoid lncRNA modulation leads to a significant reduction in micro vessel density, expression of VEGF, and tumor burden. Improved bioavailability with more advanced nanoformulation and enhancement in preclinical validation of flavonoid lncRNA therapeutics, despite the remaining challenges like limited clinical data and off-target effects, offer low-toxicity targeted means of reprogramming tumor angiogenesis and overcoming resistance to the current therapies.

These findings demonstrate that UCA1 and MALAT1 enable early identification of sorafenib resistance. Baseline stratification and serial monitoring can provide early detection of treatment resistance, informing clinical decision-making and supporting their potential utility for personalizing therapy in advanced HCC.

Our findings are consistent with recent patents (e.g., "US20220298584A1", "EP3892280A3", "WO2023147669A1") that propose the use of noncoding RNAs and cytokines as biomarkers for COVID-19 diagnosis and severity assessment. This integrative transcriptomic analysis highlights the regulatory role of noncoding RNAs in COVID-19 progression, exemplified by the central hub lncRNAs NEAT1 and MALAT1, which interact with inflammation- associated miRNAs and mRNA targets to modulate cytokine signaling. These findings offer specific transcriptomic biomarkers with potential for clinical application and therapeutic targeting.